PubMed Knowledge Graph 2.0: Integrating Papers, Patents, and Clinical Trials for a Comprehensive View of Biomedical Science

核心概念

PKG 2.0 is a comprehensive knowledge graph that integrates papers, patents, and clinical trials in biomedicine, providing a holistic view of the research landscape and enabling researchers to uncover patterns and insights previously obscured by siloed data.

摘要

Bibliographic Information:

Xu, J., Yu, C., Xu, J., Ding, Y., Torvik, V. I., Kang, J., Sung, M., & Song, M. (2023). PubMed knowledge graph 2.0: Connecting papers, patents, and clinical trials in biomedical science. Scientific Data, 10(1), 415. https://doi.org/10.1038/s41597-023-02450-6

Research Objective:

This paper introduces PKG 2.0, an updated version of the PubMed Knowledge Graph (PKG), aiming to address the limitations of existing knowledge graphs by integrating papers, patents, and clinical trials to provide a more comprehensive and interconnected view of biomedical research.

Methodology:

PKG 2.0 integrates data from various sources, including PubMed, ClinicalTrials.gov, USPTO, and NIH Exporter. The authors employed several techniques to link these data sources, including:

• Biomedical Entity Extraction and Relation Mapping: Using BERN2, a biomedical text mining tool, to extract and normalize biomedical entities from papers, patents, and clinical trials, and mapping their relationships using the iBKH dataset.
• Author Name Disambiguation: Combining data from Author-ity and Semantic Scholar, and training a deep neural network model to resolve conflicts and disambiguate author names across different data sources.
• Citation Integration: Integrating citation data from PubMed, NIH Open Citation Collection (NIH-OCC), and the OpenCitations Index of Crossref open DOI-to-DOI citations (COCI) to create a more complete citation network.
• Project Linking: Utilizing data from the NIH Exporter to link NIH-funded projects with their corresponding papers, patents, and clinical trials.

Key Findings:

• PKG 2.0 encompasses over 36 million papers, 1.3 million patents, and 0.48 million clinical trials, establishing fine-grained connections between these document types through bioentities, citations, disambiguated authors, and projects.
• The integration of multiple data sources and the use of advanced techniques for entity extraction, disambiguation, and linking resulted in a comprehensive and interconnected knowledge graph that provides a holistic view of the biomedical research landscape.
• PKG 2.0 has been validated using various datasets and has shown significant improvements in key tasks such as author disambiguation and biomedical entity recognition.

Main Conclusions:

PKG 2.0 offers a valuable resource for biomedical researchers, bibliometric scholars, and those engaged in literature mining by providing a comprehensive and interconnected view of the relationships between papers, patents, and clinical trials. This integration enables a deeper understanding of knowledge transfer, innovation pathways, and the overall scientific ecosystem in biomedicine.

Significance:

PKG 2.0 represents a significant advancement in knowledge graph construction for biomedical research. Its comprehensive integration of diverse data sources and sophisticated linking methodologies provide a powerful tool for exploring the complex relationships within the field, potentially leading to new discoveries and innovations.

Limitations and Future Research:

• The accuracy of author disambiguation and entity linking, while improved, can be further enhanced.
• The current version of PKG 2.0 primarily focuses on biomedical literature; expanding its scope to include other relevant data sources could provide a more holistic view of the research landscape.
• Future research could explore the development of user-friendly interfaces and tools to facilitate the exploration and analysis of the vast amount of data within PKG 2.0.

统计

PKG 2.0 encompasses over 36 million papers, 1.3 million patents, and 0.48 million clinical trials.
The dataset includes 25,597,962 rows of data linking USPTO patents and PubMed articles.
Author gender prediction covers 340,279 distinct names, representing 64% of the authors in PKG.

引用

"Academic papers, patents, and clinical trials are three distinct yet interconnected components in the realm of scholarly communication of medicine."
"Establishing a more integrated approach to these diverse knowledge repositories could significantly enrich our comprehension of the scientific ecosystem."
"PKG 2.0 is designed to address these challenges by integrating papers, patents, and clinical trials as core data, establishing fine-grained connections between these document types through bioentities, citations, disambiguated authors, and projects."

从中提取的关键见解

PubMed knowledge graph 2.0: Connecting papers, patents, and clinical trials in biomedical science

by Jian Xu, Cha... 在 arxiv.org 10-11-2024

https://arxiv.org/pdf/2410.07969.pdf

更深入的查询

How can PKG 2.0 be leveraged to facilitate drug discovery and development by identifying potential drug targets and predicting drug efficacy?

PKG 2.0 can significantly accelerate drug discovery and development by providing a powerful platform for identifying potential drug targets and predicting drug efficacy. Here's how:
1. Target Identification:

Understanding Disease Mechanisms: PKG 2.0 links genes, proteins, diseases, and drugs, enabling researchers to uncover complex relationships and pathways associated with specific diseases. By analyzing these interconnected networks, researchers can pinpoint key genes or proteins crucial for disease development or progression, making them potential drug targets.
Identifying Drug Repurposing Opportunities: PKG 2.0's integration of patents and clinical trials allows researchers to identify existing drugs that have shown promise in treating similar diseases or targeting related pathways. This facilitates drug repurposing, significantly reducing the time and cost of developing new treatments.
2. Predicting Drug Efficacy:

Analyzing Clinical Trial Data: PKG 2.0 provides access to a vast repository of clinical trial data, including patient demographics, treatment regimens, and outcomes. By applying machine learning algorithms to this data, researchers can develop predictive models to assess the efficacy of potential drug candidates for specific patient populations.
Uncovering Drug Synergies and Interactions: PKG 2.0's comprehensive knowledge base allows researchers to investigate potential drug synergies and interactions. By understanding how different drugs interact with each other and with specific biological pathways, researchers can develop more effective combination therapies and minimize adverse effects.
3. Accelerating Research and Collaboration:

Facilitating Knowledge Discovery: PKG 2.0's user-friendly interface and powerful search capabilities enable researchers to quickly access relevant information from diverse sources, fostering new insights and accelerating the research process.
Promoting Collaboration: PKG 2.0's interconnected data structure promotes collaboration among researchers from different disciplines by providing a common platform for sharing data, insights, and research findings.
By leveraging the power of PKG 2.0, researchers can significantly enhance their understanding of disease mechanisms, identify promising drug targets, predict drug efficacy, and ultimately accelerate the development of new and effective treatments.

Could the reliance on specific databases and algorithms introduce biases in the knowledge graph, potentially overlooking valuable information from less-represented research areas or groups?

Yes, the reliance on specific databases and algorithms in constructing PKG 2.0 could introduce biases, potentially leading to the underrepresentation of valuable information from certain research areas or groups. Here's why:

Database Bias: The databases used to build PKG 2.0, such as PubMed, USPTO, and ClinicalTrials.gov, may not equally represent all research areas or geographical regions. For example, research published in languages other than English or originating from developing countries might be underrepresented in these databases, leading to a skewed representation of knowledge within PKG 2.0.
Algorithm Bias: The algorithms used for entity recognition, author disambiguation, and other tasks in PKG 2.0 are trained on existing data, which can reflect historical biases. For instance, if the training data predominantly includes research from a particular demographic group, the algorithm might struggle to accurately identify or disambiguate authors from underrepresented groups, perpetuating existing disparities.
Citation Bias: Citation patterns themselves can be biased, with researchers often citing work from their own institutions or countries more frequently. This can lead to a reinforcement of existing hierarchies within the knowledge graph, potentially overlooking valuable contributions from less-cited or less-connected researchers.
Mitigating Bias:
Addressing these biases is crucial for ensuring the inclusivity and comprehensiveness of PKG 2.0. Some potential mitigation strategies include:

Expanding Data Sources: Incorporating data from a wider range of sources, including regional databases, grey literature, and non-English publications, can help address geographical and linguistic biases.
Developing Bias-Aware Algorithms: Researchers are actively developing algorithms that can detect and mitigate bias in training data, promoting fairer and more equitable knowledge representation.
Encouraging Data Sharing and Open Science Practices: Promoting open access publishing, data sharing, and collaborative research practices can help increase the visibility and representation of research from underrepresented groups.
By acknowledging and actively addressing potential biases, the developers of PKG 2.0 can ensure that the knowledge graph remains a valuable and inclusive resource for the entire biomedical research community.

How might the increasing availability of open-access data and advancements in artificial intelligence further revolutionize the construction and application of knowledge graphs in various scientific domains beyond biomedicine?

The increasing availability of open-access data and advancements in artificial intelligence (AI) are poised to revolutionize the construction and application of knowledge graphs across diverse scientific domains, extending far beyond biomedicine. Here's how:
Construction:

Automated Knowledge Extraction: AI-powered natural language processing (NLP) techniques can automatically extract entities, relationships, and facts from vast amounts of unstructured text data, such as scientific articles, patents, and technical reports. This significantly reduces the manual effort required for knowledge graph construction, enabling the creation of larger and more comprehensive knowledge graphs.
Integration of Diverse Data Sources: AI algorithms can effectively integrate data from heterogeneous sources, including databases, ontologies, and sensor networks. This allows for the creation of richer and more interconnected knowledge graphs that capture a more holistic view of complex scientific phenomena.
Real-Time Knowledge Graph Updates: AI-powered systems can continuously monitor and update knowledge graphs in real-time as new data becomes available. This ensures that the knowledge graph remains current and relevant, reflecting the latest scientific advancements.
Applications:

Accelerated Scientific Discovery: Knowledge graphs provide a powerful platform for knowledge discovery, enabling researchers to uncover hidden patterns, identify novel connections, and generate new hypotheses. AI-powered reasoning and inference engines can further enhance these capabilities, leading to faster and more efficient scientific breakthroughs.
Personalized Learning and Education: Knowledge graphs can be used to create personalized learning experiences tailored to individual student needs and learning styles. AI-powered recommendation systems can suggest relevant learning materials and provide personalized feedback, enhancing the learning process.
Data-Driven Decision Making: Knowledge graphs can support data-driven decision making in various domains, such as healthcare, finance, and environmental science. AI-powered analytics and visualization tools can help decision-makers extract actionable insights from complex data, leading to more informed and effective decisions.
Examples Beyond Biomedicine:

Materials Science: Knowledge graphs can accelerate the discovery of new materials with desired properties by integrating data from experimental results, simulations, and scientific literature.
Climate Science: Knowledge graphs can help model complex climate systems, predict future climate change impacts, and identify effective mitigation strategies by integrating data from various sources, including satellite imagery, climate models, and socioeconomic data.
Social Sciences: Knowledge graphs can be used to study social networks, analyze public opinion, and understand the spread of misinformation by integrating data from social media, news articles, and surveys.
The convergence of open-access data and AI is ushering in a new era of knowledge graph construction and application, empowering researchers, educators, and decision-makers across diverse scientific domains to tackle complex challenges and drive innovation.